Dec 18 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC - ON DEC 17, GENE MACK SUBMITTED HIS RESIGNATION AS CFO AND TREASURER OF CO EFFECTIVE IMMEDIATELY - SEC FILING.SELLAS LIFE SCIENCES GROUP INC - APPOINTED JOHN T. BURNS, CO’S VP, FINANCE AND CORPORATE CONTROLLER, AS CO’S INTERIM PRINCIPAL ACCOUNTING OFFICER.SELLAS LIFE SCIENCES GROUP - ENGAGED ALEKSEY KRYLOV AS CONSULTANT TO PROVIDE FINANCIAL SERVICES TO CO ON INTERIM BASIS FOR INITIAL TERM OF 3 MONTHS.
Full Article
Dec 12 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP - ON DEC. 5, BOARD APPROVED TERMINATION OF LICENSE AGREEMENT FOR GALE-401 BETWEEN MILLS PHARMACEUTICALS & BIOVASCULAR.SELLAS LIFE SCIENCES - PRELIM ESTIMATE OF PRE-TAX CHARGE IN QUARTER ENDED DEC 31, 2018 IN CONNECTION WITH TERMINATION OF BVI AGREEMENT IS ABOUT $9.7 MILLION.
Full Article
Nov 28 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES EXPEDITED DEVELOPMENT PATH FOR GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML) FOLLOWING FEEDBACK FROM FDA.SELLAS LIFE SCIENCES GROUP - PLANS TO PROCEED WITH A CLINICAL STUDY DESIGN AND BIOSTATISTICAL PLAN TO SUPPORT A PHASE 3 REGISTRATIONAL STUDY.SELLAS LIFE SCIENCES GROUP INC - FAST-TRACK AND ORPHAN DRUG DESIGNATIONS FOR GPS IN AML CONTINUE TO APPLY.SELLAS LIFE SCIENCES GROUP INC - AGREEMENT ON PHASE 3 STUDY IN PATIENTS IN CR2 POISED TO REDUCE SAMPLE SIZE, TIME TO PRIMARY ENDPOINT AND COSTS.
Full Article
Nov 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.53.SELLAS LIFE SCIENCES GROUP QTRLY LOSS PER SHARE $0.53.SELLAS LIFE SCIENCES GROUP - AS OF SEPT 30, 2018, UNRESTRICTED CASH AND CASH EQUIVALENTS TOTALED $10.0 MILLION.
Full Article
Oct 19 (Reuters) - Sellas Life Sciences Group Inc ::DATA SAFETY MONITORING BOARD CONFIRMS TRIPLE NEGATIVE BREAST CANCER AS THE TARGET PATIENT POPULATION FOR DEVELOPMENT OF NEUVAX™ (NELIPEPIMUT-S) IN COMBINATION WITH TRASTUZUMAB (HERCEPTIN®) IN HER2 1+/2+ BREAST CANCER PATIENTS FOLLOWING FINAL ANALYSIS OF PHASE 2B TRIAL.SELLAS LIFE SCIENCES - FINAL ANALYSIS SHOWED NO NEW SAFETY SIGNALS, SHOWED NO DIFFERENCE IN CARDIOTOXICITY BETWEEN TZ + NPS COMPARED TO TZ ALONE.SELLAS LIFE SCIENCES - DATA SAFETY MONITORING BOARD CONCLUDED FINAL DATA FROM PHASE 2B STUDY OF TRASTUZUMAB CONFIRMS PREVIOUSLY ANNOUNCED FINDINGS.SELLAS LIFE SCIENCES GROUP INC - DSMB CONCLUDED THAT THERE WAS AN INCREMENTAL IMPROVEMENT IN OUTCOMES AND STATISTICS WITH A LONGER MEDIAN FOLLOW-UP.
Full Article
Aug 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.26.AS OF JUNE 30, 2018, CASH AND CASH EQUIVALENTS WERE $1.3 MILLION.
Full Article
July 19 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO 9.4 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.
Full Article
July 18 (Reuters) - Sellas Life Sciences Group Inc ::EMPERY ASSET MANAGEMENT, LP REPORTS 9.99 PERCENT PASSIVE STAKE IN SELLAS LIFE SCIENCES GROUP INC AS OF JULY 12, 2018 - SEC FILING.
Full Article
June 26 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC SAYS OFFERING OF 6.08 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.
Full Article
Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016.
Full Article
Earnings vs. 
Estimates